IP Library Granted Patent US 8,741,265
Granted Patent B2
US 8,741,265 · App. 13/784,085 · Granted Jun 3, 2014

Penetrating pharmaceutical foam

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,741,265
App. No.
13/784,085
Granted
Jun 3, 2014
Kind
B2
Abstract

The invention relates to an alcohol-free cosmetic or pharmaceutical foam composition comprising water, a hydrophobic solvent, a surface-active agent, a gelling agent, an active component selected from the group of urea, hydroxy acid and a therapeutic enhancer and a propellant. The foam further comprises active agents and excipients with therapeutic properties having enhanced skin penetration.

Claims (51)

1. A foamable composition comprising a carrier and a liquefied or a compressed gas propellant, the carrier comprising:

i) about 0.1% to about 5% by weight of the carrier of a surface-active agent;

ii) about 2% to about 75% by weight of the carrier of a liquid, non-volatile hydrophobic solvent;

iii) about 0.01% to about 5% by weight of the carrier of a gelling agent; and

iv) water,

wherein the surface active agent is selected from the group consisting of polysorbate, a polyoxyethylene fatty acid ester, a polyoxyethylene alkyl ether, a sucrose ester, a partial ester of sorbitol, a partial ester of sorbitol anhydride, sodium methyl cocoyl taurate, sodium methyl oleoyl taurate, sodium lauryl sulfate, triethanolamine lauryl sulfate, a betaine, a mono-, di- or tri-ester of sucrose with food fatty acids (sucrose esters), a monoglyceride, a diglyceride, polyoxyethylene (20) sorbitan monostearate, polyoxyethylene (20) sorbitan monooleate, Myrj 45 (Polyoxyethylene (8) Stearate), Myrj 49 (polyoxyethylene (20) stearate), Myrj 59 (polyoxyethylene (100) stearate), a polyoxyethylene cetyl ether, a polyoxyethylene palmityl ether, a polyethylene oxide hexadecyl ether, Brij 52 (polyoxyethylene (2) cetyl ether), Brij 56 (polyoxyethylene (10) cetyl ether), sorbitan monolaurate, isoceteth-20, cocamidopropyl betaine, and Myrj 52 (polyoxyethylene 40 stearate);

wherein a breakable foam forms upon dispensing the foamable composition.

2. The foamable composition of claim 1 , wherein the carrier further comprises a therapeutically effective amount of at least one active agent.

3. The foamable composition of claim 1 , wherein the liquefied or compressed gas propellant is at a concentration of about 3% to about 18% by weight of the carrier.

4. The foamable composition of claim 1 , wherein the carrier is an oil in water emulsion.

5. The foamable composition of claim 1 , wherein the carrier further comprises about 1% to about 30% by weight of the carrier of a therapeutic enhancer.

6. The foamable composition of claim 5 , wherein the therapeutic enhancer is selected from the group consisting of a polyhydric alcohol, propylene glycol, butylene glycol, glycerol, pentaerythritol, sorbitol, mannitol, an oligosaccharide, dimethyl isosorbide, monooleate of ethoxylated glycerides (with 8 to 10 ethylene oxide units), a polyethylene glycol 200-600, transcutol (diethylene glycol monoethyl ether), glycofurol (tetrahydrofurfuryl alcohol PEG ether), a cyclodextrin, and mixtures of any two or more thereof.

7. The foamable composition of claim 1 , wherein the breakable foam has a specific gravity of between about 0.01 g/mL and about 0.1 g/mL.

8. The foamable composition of claim 1 , wherein the carrier further comprises a foam adjuvant.

9. The foamable composition of claim 1 , wherein the hydrophobic solvent is selected from the group consisting of vegetable oil, marine oil, mineral oil, an emollient, silicone oil, a plant-derived therapeutic oil, and mixtures of any two or more thereof.

10. The foamable composition of claim 2 , wherein the active agent is selected from the group consisting of an antibacterial agent, an anti-fungal agent, an anti-viral agent, an anti-inflammatory agent, a steroid, a corticosteroid, anti-histamine, a nonsteroidal anti-inflammatory agent, an immunomodulating agent, an immunosuppressant, an anti-allergic agent, a local anesthetic agent, a keratolytically active agent, a retinoid, an insecticide, an insect repellent, an anti-cancer drug, a photodynamic therapy agent, an active agent for burns, wounds, cuts and ulcers, an anti-acne active agent, an anti-wrinkle active agent, an anti-atrophy active agent, an anti-oxidant, a radical scavenger, a self-tanning active agent, a skin lightening or whitening agent, an agent suitable for the treatment of a hair growth disorder, a humectant, a moisture-retaining agent, a hydroxy acid, an agent for treating cellulite, and mixtures of any two or more thereof.

11. The foamable composition of claim 1 , wherein the ratio between the surface active agent and the hydrophobic solvent is between about 1:8 and about 1:16.

12. The foamable composition of claim 1 , wherein the ratio between the surface active agent and the hydrophobic solvent is between about 1:16 and about 1:32.

13. The foamable composition of claim 1 , wherein the carrier contains no more than 7.5% by weight of the carrier of methyl alcohol, ethyl alcohol, isopropyl alcohol, butyl alcohol, or mixtures thereof.

14. A foamable composition comprising a carrier and a liquefied or a compressed gas propellant, the carrier comprising:

i) about 0.1% to about 5% by weight of the carrier of a surface-active agent;

ii) 0.01% to about 5% by weight of the carrier of a gelling agent;

iii) a therapeutic enhancer selected from the group consisting of a polyhydric alcohol, propylene glycol, butylene glycol, glycerol, pentaerythritol, sorbitol, mannitol, an oligosaccharide, dimethyl isosorbide, monooleate of ethoxylated glycerides (with 8 to 10 ethylene oxide units), a polyethylene glycol 200-600, transcutol (diethylene glycol monoethyl ether), glycofurol (tetrahydrofurfuryl alcohol PEG ether), a cyclodextrin, and mixtures of any two or more thereof; and

iv) water,

wherein a breakable foam forms upon dispensing the foamable composition.

15. The foamable composition of claim 14 , wherein the liquefied or compressed gas propellant is at a concentration of about 3% to about 18% by weight of the carrier.

16. The foamable composition of claim 14 , wherein the carrier further comprises a therapeutically effective amount of at least one active agent.

17. The foamable composition of claim 14 , wherein the active agent is selected from the group consisting of an antibacterial agent, an anti-fungal agent, an anti-viral agent, an anti-inflammatory agent, a steroid, a corticosteroid, anti-histamine, a nonsteroidal anti-inflammatory agent, an immunomodulating agent, an immunosuppressant, an anti-allergic agent, a local anesthetic agent, a keratolytically active agent, a retinoid, an insecticide, an insect repellent, an anti-cancer drug, a photodynamic therapy agent, an active agent for burns, wounds, cuts and ulcers, an anti-acne active agent, an anti-wrinkle active agent, an anti-atrophy active agent, an anti-oxidant, a radical scavenger, a self-tanning active agent, a skin lightening or whitening agent, an agent suitable for the treatment of a hair growth disorder, a humectant, a moisture-retaining agent, a hydroxy acid, an agent for treating cellulite, and mixtures of any two or more thereof.

18. A foamable composition comprising a carrier and a liquefied or a compressed gas propellant, the carrier comprising:

i) about 0.1% to about 5% by weight of the carrier of a surface-active agent;

ii) about 2% to about 75% by weight of the carrier of a liquid, non-volatile hydrophobic solvent;

iii) about 0.01% to about 5% by weight of the carrier of a gelling agent;

iv) a foam adjuvant; and

iv) water,

wherein a breakable foam forms upon dispensing the foamable composition.

19. The foamable composition of claim 18 , wherein the surface-active agent is selected from the group consisting of a non ionic surface-active agent, a cationic surface-active agent, an amphoteric surface-active agent, a zwitterionic-surface active agent, and mixtures of any two or more thereof.

20. A foamable composition comprising a carrier and a liquefied or a compressed gas propellant, the carrier comprising:

i) about 0.1% to about 5% by weight of the carrier of a surface-active agent;

ii) about 2% to about 75% by weight of the carrier of a liquid, non-volatile hydrophobic solvent;

iii) about 0.01% to about 5% by weight of the carrier of a gelling agent; and

iv) water,

wherein the ratio of surface active agent to hydrophobic solvent is about 1:8 to about 1:16; and

wherein a breakable foam forms upon dispensing the foamable composition.

21. The foamable composition of claim 18 , wherein the surface-active agent is a non-ionic surfactant.

22. The foamble composition of claim 18 , wherein the carrier further comprises a therapeutically effective amount of at least one active agent.

23. The foamble composition of claim 22 , wherein the active agent is selected from the group consisting of an antibacterial agent, an anti-fungal agent, an anti-viral agent, an anti-inflammatory agent, a steroid, a corticosteroid, anti-histamine, a nonsteroidal anti-inflammatory agent, an immunomodulating agent, an immunosuppressant, an anti-allergic agent, a local anesthetic agent, a keratolytically active agent, a retinoid, an insecticide, an insect repellent, an anti-cancer drug, a photodynamic therapy agent, an active agent for burns, wounds, cuts and ulcers, an anti-acne active agent, an anti-wrinkle active agent, an anti-atrophy active agent, an anti-oxidant, a radical scavenger, a self-tanning active agent, a skin lightening or whitening agent, an agent suitable for the treatment of a hair growth disorder, a humectant, a moisture-retaining agent, a hydroxy acid, an agent for treating cellulite, and mixtures of any two or more thereof.

24. The foamable composition of claim 20 , wherein the surface-active agent is a mixture of a non ionic surface-active agent and an ionic surface-active agent in a 1:1 to 20:1 ratio.

25. The foamble composition of claim 20 , wherein the hydrophobic solvent is about 20% to about 50% by weight of the carrier.

26. The foamble composition of claim 20 , wherein the hydrophobic solvent is 10% to about 20% by weight of the carrier.

27. The foamble composition of claim 20 , wherein the carrier further comprises a therapeutically effective amount of at least one active agent.

28. The foamble composition of claim 27 , wherein the active agent is selected from the group consisting of an antibacterial agent, an anti-fungal agent, an anti-viral agent, an anti-inflammatory agent, a steroid, a corticosteroid, anti-histamine, a nonsteroidal anti-inflammatory agent, an immunomodulating agent, an immunosuppressant, an anti-allergic agent, a local anesthetic agent, a keratolytically active agent, a retinoid, an insecticide, an insect repellent, an anti-cancer drug, a photodynamic therapy agent, an active agent for burns, wounds, cuts and ulcers, an anti-acne active agent, an anti-wrinkle active agent, an anti-atrophy active agent, an anti-oxidant, a radical scavenger, a self-tanning active agent, a skin lightening or whitening agent, an agent suitable for the treatment of a hair growth disorder, a humectant, a moisture-retaining agent, a hydroxy acid, an agent for treating cellulite, and mixtures of any two or more thereof.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE PHARMACEUTICALS LTD. (F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057544/0138 →
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057544/0708 →
PATENT SECURITY AGREEMENT Recorded Feb 17, 2021
From: VYNE THERAPEUTICS INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 055326/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: VYNE PHARMACEUTICALS LTD.
To: VYNE THERAPEUTICS INC.
Reel/Frame 055215/0298 →
CHANGE OF NAME Recorded Nov 4, 2020
From: FOAMIX PHARMACEUTICALS LTD.
To: VYNE PHARMACEUTICALS LTD.
Reel/Frame 054306/0387 →
PATENT SECURITY AGREEMENT Recorded Jul 30, 2019
From: FOAMIX PHARMACEUTICALS LTD
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 049912/0045 →
CHANGE OF NAME Recorded Jul 30, 2014
From: FOAMIX LTD.
To: FOAMIX PHARMACEUTICALS LTD.
Reel/Frame 033445/0249 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2013
From: TAMARKIN, DOV; FRIEDMAN, DORON; EINI, MEIR
To: FOAMIX LTD.
Reel/Frame 030240/0561 →